TNF Superfamily Antagonism
BITT’s dominant antibody antagonist antibody platform (DOMabTM) is a proprietary discovery platform for the development of antagonist monoclonal antibodies to the TNF superfamily. DOMab antibodies create unique surface stabilization of anti-parallel dimers for altering intracellular signaling. For TNF superfamily proliferative pathways (such as TNFR2, TRAIL and HVEM), antagonism causes cell death. For death receptors (such as CD40, CD27 and OX40), antagonism permits cell growth. Our technology’s ability to create antibodies that target only rapidly proliferating cells opens the door to TNF superfamily targets that were previously considered undruggable or limited by toxicology.